ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 1200

Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo

Philip G. Conaghan1, Francis Berenbaum2, Virginia B. Kraus3, James Johnson4 and Scott Kelley5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Pierre & Marie Curie University, Saint-Antoine Hospital, Paris, France, 3Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 4Summit Analytical, Denver, CO, 5Flexion Therapeutics, Inc., Burlington, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Clinical, corticosteroids, Knee, meta-analysis and osteoarthritis

Session Information

Date: Monday, November 6, 2017

Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A recent meta-analysis concluded that intra-articular corticosteroids (IACS) for knee osteoarthritis (OA) may be associated with moderate improvement in pain compared with control treatment.1,2 Notably, evidence quality was graded “low” due in part to inclusion of many small trials and trial heterogeneity.1,2  Only 3 trials were moderate to large in size (≥50 patients/arm), with a variety of control treatments and pain endpoints. Across those 3 trials, at 1–2 weeks, 4–6 weeks, and 3 months post-treatment, standardized mean difference (SMD) corresponded to numbers needed to treat (NNT) of 8, 15, and infinity (indicating that the benefit of treatment cannot be determined; Figure).2 FX006 is an extended-release formulation of triamcinolone acetonide for IA injection. We updated the meta-analysis by including data from two large, randomized, placebo-controlled trials of FX006 in patients with knee OA and heuristically compared the analysis of FX006 to the moderate to large trials to help assess the clinical relevance of FX006.

Methods: In studies FX006-2014-006 (NCT02116972) and FX006-2014-008 (NCT02357459), knee OA patients (Kellgren-Lawrence Grade 2 or 3; Average Daily Pain (ADP)-intensity ≥5–≤9) received a single IA injection of FX006 40 mg (N=104 and N=161, respectively) or saline-placebo (N=104 and N=163, respectively). ADP was collected for 24 weeks post-injection. SMD (95% CI) was computed for ADP-intensity at 2 weeks, 6 weeks, and 3 months post-treatment using least-squares mean (LSM) difference for FX006 from saline-placebo derived from each trial. Weighted-average SMD (95% CI) for FX006 and corresponding NNT for FX006 vs saline-placebo were determined and compared to NNTs reported for IACS.1,2

Results: FX006 yielded a weighted average SMD (95% CI) of −0.51 (−0.72, −0.31), −0.56 (−0.74, −0.36), and −0.34 (−0.52, −0.14) at 2 weeks, 6 weeks, and 3 months post-treatment, respectively, corresponding to a NNT (95% CI) of 4 (1 to 7), 4 (1 to 6), and 10 (7 to 13) at the corresponding time points (Figure). The magnitude of the FX006 effect is favorable compared with that determined for IACS, with a lower NNT (pooled estimate):  4 vs 8 (1–2 weeks), 4 vs 15 (4–6 weeks), and 10 vs infinity (3 months).

Conclusion: The two large FX006 studies in the expanded analysis demonstrated effective analgesia through 3 months with reduced NNT compared with traditional IACS. Limitations of the heuristic comparison include small sample sizes, trial heterogeneity, non-placebo controls, and other factors among the comparator trials.

1Juni P, et al. Cochrane Database Syst Rev. 2015;22:CD005328.

2da Costa BR, et al. JAMA. 2016;316:2671-2.

 



Disclosure: P. G. Conaghan, Novartis Pharmaceutical Corporation, 5,Flexion Therapeutics, 5,AbbVie, 5,Infirst, 5,Medivir, 5,Merck Serono, 5,ONO Pharmaceutical Co., 5; F. Berenbaum, Fondation Arthritis, 2,FOREUM Foundation, 2,Pfizer Inc, 2,Programme Europeen de Recherche, 2,Servier, 2,Societe Francaise de Rhumatologie, 2,TRB Chemedica, 2,AbbVie, 5,Biogaran, 5,Biogen, 5,Expanscience, 5,Flexion Therapeutics, 5,IBSA, 5,Janssen Pharmaceutica Product, L.P., 5,Merck Serono, 5,Novartis, 5,Pfizer, 5,Sanofi-Aventis Pharmaceutical, 5,Servier, 5,TRB Chemedica, 5,UCB, 5,OARSI, 9,Pfizer Inc, 9,US Arthritis Foundation, 9; V. B. Kraus, Flexion Therapeutics, 5; J. Johnson, Flexion Therapeutics, 1,Flexion Therapeutics, 3,Flexion Therapeutics, 5,Summit Analytical, LLC, 3,Acura Pharmaceuticals, 5,Iroko Pharmaceuticals, 5,IX Biopharma, 5,Tolmar, Inc., 5; S. Kelley, Flexion Therapeutics, 1,Flexion Therapeutics, 3.

To cite this abstract in AMA style:

Conaghan PG, Berenbaum F, Kraus VB, Johnson J, Kelley S. Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/updating-the-knee-osteoarthritis-intra-articular-corticosteroid-meta-analysis-with-two-large-trials-of-extended-release-triamcinolone-acetonide-fx006-versus-placebo/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/updating-the-knee-osteoarthritis-intra-articular-corticosteroid-meta-analysis-with-two-large-trials-of-extended-release-triamcinolone-acetonide-fx006-versus-placebo/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology